PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-854

don’t want a partnership deal too early.

I would expect that there is another raise from OLE or strike readouts ( on release) we missed that boat last time. It’s worked well for DXB and BOT. Need cash to be in a strong position of negotiation.

SPP should retain any oversubscription to reward holders, but this would add further dilution so they may want to scale back and rise at higher price - either way it would show confidence.

The $1m question, interestingly requires shareholder approval which will be at the AGM. So they don’t need to commit now and get the benefit of any interim news / progress. May say oversubscribed so don’t need to put it $1m but if they still do another vote of confidence.

Interesting to see SPP results, the MND story is quite recent so long term shareholders may not be as bullish? Also economy impacting everyone differently, but seeing other recent SPP and raises expecting significantly oversubscribed, if not market is really overlooking this opportunity.

p.s. In terms of catalysts - neurodegenerative preclinicals will send a message, I’m optimistic this will be positive based on the science.